QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=AFB63DDE61A8723B740184E22BB8F0FD;jsessionid=9B14B8017945E5597AE851095E55D9EE;jsessionid=4A3B0BA182CA1C9258DCC637B3B7F1BD;jsessionid=111C8FD6059ECD775B9333F7C00939D3;jsessionid=488B57B2AA279B7DD3EACCB9D42B47F6;jsessionid=1E8EF483760088CE5FD93955BFA6A29B;jsessionid=35056953A0C40E44786B6EB1220A76AF (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=AFB63DDE61A8723B740184E22BB8F0FD;jsessionid=9B14B8017945E5597AE851095E55D9EE;jsessionid=4A3B0BA182CA1C9258DCC637B3B7F1BD;jsessionid=111C8FD6059ECD775B9333F7C00939D3;jsessionid=488B57B2AA279B7DD3EACCB9D42B47F6;jsessionid=1E8EF483760088CE5FD93955BFA6A29B;jsessionid=35056953A0C40E44786B6EB1220A76AF